Your Voice

Article

Questioning the data on outcomes and satisfaction with PNP care. Bedwetting dishonesty can't be justified. Prevalance of autism: What the data show.

Recent Videos
Jenna Marcovitz, MA explains how music therapy helps in pediatric care
Peter S. Jensen, MD
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital | Image credit: Boston Children's
Joshua Feder, MD
Zika-based therapy for metastatic neuroblastoma with Tamarah Westmoreland, MD and Joseph Mazar, PhD | Image Credit: © Nemours- © Nemours - stock.adobe.com.
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Related Content
Connecting families to music therapy, with Jenna Marcovitz, MA

Connecting families to music therapy, with Jenna Marcovitz, MA

Jenna Marcovitz, MA, MT-BC, CCLS, RMT
May 15th 2025
Article

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Phase 3 data show effectiveness of somapacitan in children with growth disorders | Image Credit: © Saiful52- © Saiful52 - stock.adobe.com.

Phase 3 data show effectiveness of somapacitan in children with growth disorders

Joshua Fitch, Senior Editor
May 15th 2025
Article

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Inozyme Pharma

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients

Morgan Ebert, Managing Editor
May 14th 2025
Article

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.

FDA accepts NDA for berotralstat in HEA patients aged 2 to 11 years | Image credit: Contemporary Pediatrics

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

Joshua Fitch, Senior Editor
May 14th 2025
Article

The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO).

© 2025 MJH Life Sciences

All rights reserved.